blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3262168

EP3262168 - HOST CELL PROTEIN MODIFICATION [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  19.03.2021
Database last updated on 31.08.2024
FormerThe patent has been granted
Status updated on  19.07.2019
FormerGrant of patent is intended
Status updated on  31.01.2019
FormerExamination is in progress
Status updated on  01.06.2018
FormerRequest for examination was made
Status updated on  01.12.2017
FormerThe international publication has been made
Status updated on  15.08.2017
Most recent event   Tooltip20.06.2024Lapse of the patent in a contracting state
New state(s): CY		published on 24.07.2024  [2024/30]
Applicant(s)For all designated states
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591 / US
[2019/34]
Former [2018/01]For all designated states
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591 / US
Inventor(s)01 / BURAKOV, Darya
c/o Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591 / US
02 / GOREN, Michael
c/o Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591 / US
03 / CHEN, Gang
c/o Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591 / US
 [2018/01]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2019/34]
Former [2018/01]J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date16710378.726.02.2016
[2018/01]
WO2016US19915
Priority number, dateUS201562126213P27.02.2015         Original published format: US 201562126213 P
US201662298869P23.02.2016         Original published format: US 201662298869 P
[2018/01]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016138467
Date:01.09.2016
Language:EN
[2016/35]
Type: A1 Application with search report 
No.:EP3262168
Date:03.01.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 01.09.2016 takes the place of the publication of the European patent application.
[2018/01]
Type: B1 Patent specification 
No.:EP3262168
Date:21.08.2019
Language:EN
[2019/34]
Search report(s)International search report - published on:EP01.09.2016
ClassificationIPC:C12N15/09
[2018/01]
CPC:
C07K16/00 (EP,CN,US); C12N15/85 (KR,US); C12N15/09 (EP,CN,US);
C07K1/18 (KR); C07K1/22 (KR); C12N5/0602 (KR);
C12N9/18 (KR); C12N9/20 (EP,US); C07K2317/14 (EP,CN,US);
C12N2510/02 (KR); C12Y301/01 (KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/01]
Extension statesBA14.08.2017
ME14.08.2017
Validation statesMA14.08.2017
MD14.08.2017
TitleGerman:WIRTSZELLENPROTEINMODIFIKATION[2018/01]
English:HOST CELL PROTEIN MODIFICATION[2018/01]
French:MODIFICATION DE PROTÉINES DE CELLULES HÔTES[2018/01]
Entry into regional phase14.08.2017National basic fee paid 
14.08.2017Designation fee(s) paid 
14.08.2017Examination fee paid 
Examination procedure14.08.2017Amendment by applicant (claims and/or description)
14.08.2017Examination requested  [2018/01]
14.08.2017Date on which the examining division has become responsible
04.06.2018Despatch of a communication from the examining division (Time limit: M06)
14.12.2018Reply to a communication from the examining division
01.02.2019Communication of intention to grant the patent
10.06.2019Fee for grant paid
10.06.2019Fee for publishing/printing paid
10.06.2019Receipt of the translation of the claim(s)
Opposition(s)Opponent(s)01  21.05.2020  25.05.2020  ADMISSIBLE
Dr. H. Ulrich Dörries
Fünf Höfe, Theatinerstr. 16
80333 München / DE
Opponent's representative
Dörries, Hans Ulrich
df-mp
Fünf Höfe
Theatinerstrasse 16
80333 München / DE
 [2020/27]
16.06.2020Invitation to proprietor to file observations on the notice of opposition
26.11.2020Reply of patent proprietor to notice(s) of opposition
01.12.2020Despatch of communication that the patent will be revoked
11.12.2020Legal effect of revocation of patent [2021/16]
Fees paidRenewal fee
22.02.2018Renewal fee patent year 03
20.02.2019Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL21.08.2019
AT21.08.2019
CY21.08.2019
EE21.08.2019
FI21.08.2019
HR21.08.2019
LT21.08.2019
LV21.08.2019
MC21.08.2019
MK21.08.2019
PL21.08.2019
RO21.08.2019
RS21.08.2019
SI21.08.2019
SK21.08.2019
SM21.08.2019
TR21.08.2019
BG21.11.2019
GR22.11.2019
IS21.12.2019
PT23.12.2019
LU26.02.2020
[2024/30]
Former [2022/32]AL21.08.2019
AT21.08.2019
EE21.08.2019
FI21.08.2019
HR21.08.2019
LT21.08.2019
LV21.08.2019
MC21.08.2019
MK21.08.2019
PL21.08.2019
RO21.08.2019
RS21.08.2019
SI21.08.2019
SK21.08.2019
SM21.08.2019
TR21.08.2019
BG21.11.2019
GR22.11.2019
IS21.12.2019
PT23.12.2019
LU26.02.2020
Former [2020/50]AL21.08.2019
AT21.08.2019
EE21.08.2019
FI21.08.2019
HR21.08.2019
LT21.08.2019
LV21.08.2019
MC21.08.2019
PL21.08.2019
RO21.08.2019
RS21.08.2019
SI21.08.2019
SK21.08.2019
SM21.08.2019
TR21.08.2019
BG21.11.2019
GR22.11.2019
IS21.12.2019
PT23.12.2019
LU26.02.2020
Former [2020/48]AL21.08.2019
AT21.08.2019
EE21.08.2019
FI21.08.2019
HR21.08.2019
LT21.08.2019
LV21.08.2019
PL21.08.2019
RO21.08.2019
RS21.08.2019
SI21.08.2019
SK21.08.2019
SM21.08.2019
TR21.08.2019
BG21.11.2019
GR22.11.2019
IS21.12.2019
PT23.12.2019
LU26.02.2020
Former [2020/37]AL21.08.2019
AT21.08.2019
EE21.08.2019
FI21.08.2019
HR21.08.2019
LT21.08.2019
LV21.08.2019
PL21.08.2019
RO21.08.2019
RS21.08.2019
SI21.08.2019
SK21.08.2019
SM21.08.2019
TR21.08.2019
BG21.11.2019
GR22.11.2019
IS21.12.2019
PT23.12.2019
Former [2020/36]AL21.08.2019
AT21.08.2019
EE21.08.2019
FI21.08.2019
HR21.08.2019
LT21.08.2019
LV21.08.2019
PL21.08.2019
RO21.08.2019
RS21.08.2019
SK21.08.2019
SM21.08.2019
TR21.08.2019
BG21.11.2019
GR22.11.2019
IS21.12.2019
PT23.12.2019
Former [2020/27]AL21.08.2019
AT21.08.2019
EE21.08.2019
FI21.08.2019
HR21.08.2019
LT21.08.2019
LV21.08.2019
PL21.08.2019
RO21.08.2019
RS21.08.2019
SK21.08.2019
SM21.08.2019
TR21.08.2019
BG21.11.2019
GR22.11.2019
PT23.12.2019
IS24.02.2020
Former [2020/25]AL21.08.2019
AT21.08.2019
EE21.08.2019
FI21.08.2019
HR21.08.2019
LT21.08.2019
LV21.08.2019
PL21.08.2019
RO21.08.2019
RS21.08.2019
SK21.08.2019
TR21.08.2019
BG21.11.2019
GR22.11.2019
PT23.12.2019
IS24.02.2020
Former [2020/24]AL21.08.2019
AT21.08.2019
EE21.08.2019
FI21.08.2019
HR21.08.2019
LT21.08.2019
LV21.08.2019
PL21.08.2019
RO21.08.2019
RS21.08.2019
TR21.08.2019
BG21.11.2019
GR22.11.2019
PT23.12.2019
IS24.02.2020
Former [2020/23]AL21.08.2019
AT21.08.2019
EE21.08.2019
FI21.08.2019
HR21.08.2019
LT21.08.2019
LV21.08.2019
PL21.08.2019
RO21.08.2019
RS21.08.2019
TR21.08.2019
BG21.11.2019
GR22.11.2019
IS21.12.2019
PT23.12.2019
Former [2020/22]AL21.08.2019
EE21.08.2019
FI21.08.2019
HR21.08.2019
LT21.08.2019
LV21.08.2019
RS21.08.2019
TR21.08.2019
BG21.11.2019
GR22.11.2019
IS21.12.2019
PT23.12.2019
Former [2020/17]AL21.08.2019
FI21.08.2019
HR21.08.2019
LT21.08.2019
LV21.08.2019
RS21.08.2019
TR21.08.2019
BG21.11.2019
GR22.11.2019
IS21.12.2019
PT23.12.2019
Former [2020/15]AL21.08.2019
FI21.08.2019
HR21.08.2019
LT21.08.2019
LV21.08.2019
RS21.08.2019
BG21.11.2019
GR22.11.2019
IS21.12.2019
PT23.12.2019
Former [2020/12]FI21.08.2019
HR21.08.2019
LT21.08.2019
LV21.08.2019
RS21.08.2019
BG21.11.2019
GR22.11.2019
IS21.12.2019
PT23.12.2019
Former [2020/10]FI21.08.2019
LT21.08.2019
BG21.11.2019
PT23.12.2019
Former [2020/09]FI21.08.2019
LT21.08.2019
Former [2020/08]LT21.08.2019
Cited inInternational search[XY]  - KIM DAESOO ET AL, "Phospholipase C isozymes selectively couple to specific neurotransmitter receptors", NATURE (LONDON), (1997), vol. 389, no. 6648, ISSN 0028-0836, pages 290 - 293, XP002757066 [X] 1-12 * the whole document * [Y] 13-24

DOI:   http://dx.doi.org/10.1038/38508
 [XY]  - KURIAN MANJU A ET AL, "Phospholipase C beta 1 deficiency is associated with early-onset epileptic encephalopathy", BRAIN, (201010), vol. 133, no. Part 10, pages 2964 - 2970, XP002757067 [X] 1-12 * the whole document * [Y] 13-24

DOI:   http://dx.doi.org/10.1093/brain/awq238
 [X]  - BOGARAPU SOUJANYA ET AL, "Phenotype of a Patient With Contiguous Deletion of TBX5 and TBX3: Expanding the Disease Spectrum", AMERICAN JOURNAL OF MEDICAL GENETICS, (201405), vol. 164, no. 5, pages 1304 - 1309, XP002757068 [X] 1-24 * the whole document *

DOI:   http://dx.doi.org/10.1002/ajmg.a.36447
 [A]  - BRUNTZ RONALD C ET AL, "Phospholipase D Signaling Pathways and Phosphatidic Acid as Therapeutic Targets in Cancer", PHARMACOLOGICAL REVIEWS, (201410), vol. 66, no. 4, pages 1033 - 1079, XP002757069 [A] 1-24 * the whole document *

DOI:   http://dx.doi.org/10.1124/pr.114.009217
by applicantUS7771997
    - SCHENAUER, MR. ET AL., BIOTECHNOL PROG, (2013), vol. 29, no. 4, pages 951 - 957
    - TAIT ET AL., BIOTECHNOL PROG, (2013), vol. 29, no. 3, pages 688 - 696
    - LABRENZ, S.R., "Ester hydrolysis of polysorbate 80 in mAb drug product: evidence in support of the hypothesized risk after observation of visible particulate in mAb formulations", J. PHARMA. SCI., (2014), vol. 103, no. 8, doi:doi:10.1002/jps.24054, pages 2268 - 77, XP055514263

DOI:   http://dx.doi.org/10.1002/jps.24054
    - UPTON, C; BUCKLEY, JT, "A new family of lipolytic enzymes?", TRENDS BIOCHEM SCI., (1995), vol. 20, doi:doi:10.1016/S0968-0004(00)89002-7, pages 178 - 179, XP004222260

DOI:   http://dx.doi.org/10.1016/S0968-0004(00)89002-7
    - REPO, H. ET AL., PROTEINS, (2014), vol. 82, pages 300 - 311
    - KANOH, H. ET AL., COMP BIOCHEM PHYSIOL, (1991), vol. 102B, no. 2, pages 367 - 369
    - BOCH J ET AL., SCIENCE, (2009), vol. 326, pages 1509 - 1512
    - BOGDANOVE, A. J.; VOYTAS, D. F., SCIENCE, (2011), vol. 333, pages 1843 - 1846
    - MILLER, J. C. ET AL., NAT BIOTECHNOL, (2011), vol. 29, pages 143 - 148
    - STELLA, S. ET AL., ACTA CRYST., (2014), vol. D70, pages 2042 - 2052
    - METH. ENZYMOLOGY, (1988), vol. 185, page 537
    - WIGLER ET AL., PROC. NATL. ACAD. SCI. USA, (1980), vol. 77, page 3567
    - SCHAFFNER ET AL., PROC. NATL. ACAD. SCI. USA, (1980), vol. 77, page 2163
    - POTTER ET AL., PROC. NATL. ACAD. SCI. USA, (1988), vol. 81, page 7161
    - SHIGEKAWA ET AL., BIOTECHNIQUES, (1988), vol. 6, page 742
    - SAMBROOK, Molecular Biology: A Laboratory Manual, COLD SPRING HARBOR LABORATORY, (1989), pages 16.9 - 16.14
OppositionUS15055034
 WO2015038888
 WO2015095568
    - WANG X et al., "Host cell proteins in biologics development: Identification, quantitation and risk assessment", Biotechnology and Bioengineering, vol. 103, no. 3, (20090400), pages 446 - 458, XP002546192

DOI:   http://dx.doi.org/10.1002/BIT.22304
    - HOGWOOD C E M et al., "Measurement and control of host cell proteins (HCPs) in CHO cell bioprocesses", Current Opinion in Biotechnology, (20141200), vol. 30, pages 153 - 160, XP055378440

DOI:   http://dx.doi.org/10.1016/j.copbio.2014.06.017
    - VALENTE K et al., "Expression of Difficult-to-Remove Host Cell Protein Impurities During Extended Chinese Hamster Ovary Cell Culture and Their Impact on Continuous Bioprocessing", Biotechnology and Bioengineering, vol. 112, no. 6, (20150116), pages 1232 - 1242, XP002796221

DOI:   http://dx.doi.org/10.1002/bit.25515
    - JOUCLA G et al., "Cation exchange versus multimodal cation exchange resins for antibody capture from CHO supernatants: Identification of contaminating Host Cell Proteins by mass spectrometry", J of Chromatography B, (20131200), vol. 942-943, pages 126 - 133, XP028788271

DOI:   http://dx.doi.org/10.1016/j.jchromb.2013.10.033
    - ABOULAICH N et al., "A novel approach to monitor clearance of host cell proteins associated with monoclonal antibodies", Biotechnol Prog., vol. 30, no. 5, (20140700), pages 1114 - 1124, XP055425286

DOI:   http://dx.doi.org/10.1002/btpr.1948
    - RONDA C et al., "Accelerating genome editing in CHO cells using CRISPR Cas9 and CRISPy, a web-based target finding tool", Biotechnology and Bioengineering, (20140800), vol. 111, no. 8, pages 1604 - 1616, XP055244605

DOI:   http://dx.doi.org/10.1002/bit.25233
    - BRINKROLF K et al., "Chinese hamster genome sequenced from sorted chromosomes", Nature Biotechnology, (20130000), vol. 31, pages 694 - 695, XP055721392

DOI:   http://dx.doi.org/10.1038/nbt.2645
    - XU X et al., "The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line", Nature Biotechnology, (20110000), vol. 29, no. 8, pages 735 - 742, XP055223996

DOI:   http://dx.doi.org/10.1038/nbt.1932
    - GAO S X et al., "fragmentation of a highly purified monoclonal antibody attributed to residual CHO cell protease activity", Biotechnology and Bioengineering., (20110000), vol. 2011, no. 4, pages 977 - 982, XP055721400

DOI:   http://dx.doi.org/10.1002/bit.22982
    - VANDERLAAN M, "hamster phospholipase B-like 2 (PLBL2) A host cell protein impurity in cho-derived therapeutic monoclonal antibodies", CaSSS CMC Strategy Form, Washington DC, (20150125), XP055337487
    - LEVY N, "Host cell protein impurities and protein-protein interactions in downstream purification of monoclonal", Dissertation, (20141100), XP055682644

DOI:   http://dx.doi.org/10.1002/bit.25882
    - VANDERLAAN M et al., "Polyurethanes from ALCELL LIGNIN", Bioprocess International, (20150414), vol. 13, no. 14, pages 18 - 25, XP002720465

DOI:   http://dx.doi.org/10.1016/S0961-9534(97)00030-5
    - HANANIA N A et al., "lebrikizumab in moderate to servere asthma pooled data from two randomised placebo controlled studies", Thorax, vol. 70, no. 8, (20150500), pages 748 - 56, XP055721414
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.